[Evaluation of a telemedicine system for the transmission of morpho/immunological data at the inclusion of patients in a therapeutic trial (Goelams LLC 98)].
The performances of the images digitalization and teletransmission systems make them more and more used. Applied to cellular haematology, they contribute to confrontations of diagnosis mostly within the framework of therapeutic trials. We present one of the first approaches of the use of telehematology for the inclusion of patients in the Goelams Chronic Lymphocytic Leukaemia 98 trial. The advantages were the constitution of a protected data bank, conveniently consultable; expertise on identical documents; facility of the exchanges between experts. We were able to set new standards of images sampling for CLL, solve the semantic divergences, to point out the inter-observer variability for the morphology. The limiting factors were the personal investment of the experts, but mainly the implication of first line morphologists which should benefit from adequate tools to apprehend this system of second reading like a quality control.
Lesesve
J-F
JF
Services d'hématologie clinique et biologique, CHU de Nancy. jf.lesesve@chu-nancy.fr
Palmiéri
A
A
Brion
A
A
Feugier
P
P
Mahé
B
B
Garand
R
R
D006801:Humans; D016130:Immunophenotyping; D007945:Leukemia, Lymphoid / Q000276:immunology* / Q000473:pathology*; D015337:Multicenter Studies as Topic; D015588:Observer Variation; D016032:Randomized Controlled Trials as Topic; D017216:Telemedicine